Table 2.
Parameter | Base-case value | Source/assumption | ||||
Probabilities | ||||||
After suspected stroke | ||||||
Standard care | 0.61 | Multimedia Appendix 4 | ||||
In-ambulance telemedicine | 0.39 | Multimedia Appendix 4 | ||||
After ischemic stroke | ||||||
IVTa | 0.19 | Multimedia Appendix 4 | ||||
EVTb | 0.07 | Multimedia Appendix 4 | ||||
Conservative treatment | 0.73 | Multimedia Appendix 4 | ||||
After ischemic stroke and IVT | ||||||
0-90 min | 0.15 | Multimedia Appendix 4 | ||||
91-180 min | 0.29 | Multimedia Appendix 4 | ||||
181-270 min | 0.56 | Multimedia Appendix 4 | ||||
After ischemic stroke and EVT | ||||||
0-180 min | 0.19 | Multimedia Appendix 4 | ||||
181-270 min | 0.23 | Multimedia Appendix 4 | ||||
271-360 min | 0.38 | Multimedia Appendix 4 | ||||
361-480 min | 0.19 | Multimedia Appendix 4 | ||||
Costs, US $ (€) | ||||||
Cost per teleconsultation | 142.89 (107.52) | Multimedia Appendix 5 | ||||
Cost of installation of 1 telemedicine device | 29,011 (26,000) | Offer from Zebra Academy | ||||
Estimated total cost for in-ambulance telemedicine for 390 treated patients in 1 year | 159,425 (119,959) | Multimedia Appendix 5 | ||||
Number of patients that can be treated with 1 device in 1 year | 150 | Activation rates of the PreSSUB-Ic trial [4] |
aIVT: intravenous administration of recombinant tissue plasminogen activator.
bEVT: endovascular treatment.
cPreSSUB-I: Prehospital Study at the Universitair Ziekenhuis Brussel I.